Answers are grounded in this paper and cite their sources.
Randomized trial shows psilocybin significantly reduces symptoms in treatment-resistant depression, indicating its potential in routine care.
The question of whether the striking antidepressant effects of psilocybin reported in randomised trials can be reproduced in everyday care remains largely unanswered. This is because those trials enrol highly selected patients, withdraw concomitant medication and deliver treatment under tightly standardised protocols. In this issue, Jungwirth et al. provide one of the first responses from routine clinical practice.1 Among 19 adults with treatment-resistant depression (TRD) who were treated with psilocybin under Switzerland’s limited medical use framework, clinician-rated symptoms decreased substantially (a Montgomery–Åsberg reduction of approximately 11 points; Hedges’ g ≈ 1.4).
No takes yet. Share an insight, caveat, or question.
Vassilis Martiadis (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: